# Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)

> **NCT03393806** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 17 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GSK3772847
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03393806
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-18
- **Primary completion:** 2019-10-09
- **Final completion:** 2020-01-06
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Recruitment was terminated early before meeting target enrolment due to a high screen failure rate and the feasibility of completing the study in a timely way
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393806, "Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03393806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*